Boehringer backs $33M cancer vaccine play at Switzerland's AMAL Therapeutics
A cancer vaccine developer spun out of the University of Geneva has garnered €29 million ($32.7 million) to fuel its drive into the clinic. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
